和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

未开盘 04-30 16:08:06

30.250

-0.750

-2.42%

最高31.150	最低29.700	成交量257.00万
今开31.150	昨收31.000	日振幅4.68%
总市值263.56亿	流通市值263.56亿	总股本8.71亿
成交额7,753万	换手率0.29%	流通股本8.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":30.25,"timestamp":1714464486023,"preClose":31,"halted":0,"volume":2570027,"delay":0,"floatShares":871256270,"shares":871256270,"eps":0.92791766,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.75,"latestTime":"04-30 16:08:06","open":31.15,"high":31.15,"low":29.7,"amount":77525197,"amplitude":0.046774,"askPrice":30.25,"askSize":25500,"bidPrice":30.2,"bidSize":38000,"shortable":3,"etf":0,"ttmEps":0.9279176380392095,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714613400000},"adr":0,"listingDate":1624982400000,"adjPreClose":31,"openAndCloseTimeList":[[1714440600000,1714449600000],[1714453200000,1714464000000]],"volumeRatio":0.5741711401714213,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2431364650","title":"和黄医药(00013)呋喹替尼欧日获批在即，海外放量可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2431364650","media":"国泰君安","top":-1,"share":"https://www.laohu8.com/m/news/2431364650?lang=zh_cn&edition=full","pubTime":"2024-04-30 15:14","pubTimestamp":1714461294,"startTime":"0","endTime":"0","summary":"摘要：事件：呋喹替尼继2023.11月美国获批后，近期欧洲药品管理局人用药品委员会给予积极意见支持呋喹替尼用于治疗经治转移性结直肠癌，有望近期获批上市。2023.9月呋喹替尼向日本递交了NDA，有望24年内获批上市。我们看好呋喹替尼海外市场进一步打开，维持“增持”评级。此外，公司有望于24年底披露呋喹替尼治疗肾细胞癌II/III期顶线结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043015321987c2b0b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043015321987c2b0b4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431488359","title":"港股概念追踪 |ASCO研究标题发布 机构关注国产创新药产业机会（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2431488359","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431488359?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:00","pubTimestamp":1714456822,"startTime":"0","endTime":"0","summary":"2024年美国临床肿瘤学会年会的研究标题于4月25日公布，纳入约5900余摘要。工银瑞信基金认为，考虑到将在二季度举办的美国临床肿瘤学会年会将有大量ADC数据读出，届时将对创新药形成催化，叠加行业本身的政策利好，长期维度来看创新药板块仍值得关注。该行看好公司作为全球实体瘤CAR-T龙头企业，其CT053、CT041等管线陆续商业化带来成长性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116125.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431671864","title":"和黄医药(US ADR)上涨4.9%，报19.05美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431671864","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431671864?lang=zh_cn&edition=full","pubTime":"2024-04-29 22:14","pubTimestamp":1714400057,"startTime":"0","endTime":"0","summary":"4月29日，和黄医药(US ADR)(HCM)盘中上涨4.9%，截至22:14，报19.05美元/股，成交166.19万美元。财务数据显示，截至2023年12月31日，和黄医药(US ADR)收入总额8.38亿美元，同比增长96.52%；归母净利润1.01亿美元，同比增长127.93%。大事提醒：5月22日，和黄医药(US ADR)将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/29221440477714.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431040747","title":"和黄医药(00013)上涨5.11%，报31.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431040747","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431040747?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:19","pubTimestamp":1714357155,"startTime":"0","endTime":"0","summary":"4月29日，和黄医药(00013)盘中上涨5.11%，截至10:19，报31.9元/股，成交3450.93万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2023年年报，和黄医药营业总收入59.35亿元、净利润7.14亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/29101940459601.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431020040","title":"和黄医药盘中异动 早盘大幅拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431020040","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431020040?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:19","pubTimestamp":1714357151,"startTime":"0","endTime":"0","summary":"2024年04月29日早盘10时19分，和黄医药股票出现异动，股价快速拉升5.10%。截至发稿，该股报31.900港元/股，成交量111.25万股，换手率0.13%，振幅6.26%。和黄医药股票所在的药品行业中，整体涨幅为0.29%。其相关个股中，泰凌医药、长江生命科技、联康生物科技集团涨幅较大，振幅较大的相关个股有三爱健康集团、泰凌医药、和黄医药，振幅分别为19.23%、11.54%、5.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042910191187e84888&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042910191187e84888&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430065498","title":"和黄医药(00013.HK)合作伙伴武田创新药呋喹替尼获CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2430065498","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430065498?lang=zh_cn&edition=full","pubTime":"2024-04-28 22:54","pubTimestamp":1714316040,"startTime":"0","endTime":"0","summary":"和黄医药公布，合作伙伴武田取得欧洲药品管理局“EMA”人用药品委员会“CHMP”建议批准呋喹替尼用于治疗经治的成人转移性结直肠癌患者。欧盟委员会 在决定呋喹替尼用于治疗转移性结直肠癌在整个欧盟、挪威、列支敦士登和冰岛的上市许可时，将会把CHMP的积极意见纳入考量。倘获批，呋喹替尼将成为欧盟批准用于经治转移性结直肠癌的第一个也是唯一一个所有三种血管内皮生长因子受体“VEGFR”的选择性抑制剂。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345625/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430052492","title":"和黄医药(US ADR)下跌5.21%，报18.0美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430052492","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430052492?lang=zh_cn&edition=full","pubTime":"2024-04-26 22:20","pubTimestamp":1714141252,"startTime":"0","endTime":"0","summary":"4月26日，和黄医药(US ADR)(HCM)盘中下跌5.21%，截至22:20，报18.0美元/股，成交72.22万美元。财务数据显示，截至2023年12月31日，和黄医药(US ADR)收入总额8.38亿美元，同比增长96.52%；归母净利润1.01亿美元，同比增长127.93%。大事提醒：5月22日，和黄医药(US ADR)将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/26222040440599.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430232208","title":"呋喹替尼获欧洲药品管理局CHMP积极意见用于结直肠癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2430232208","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2430232208?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:39","pubTimestamp":1714138740,"startTime":"0","endTime":"0","summary":"欧盟委员会在决定呋喹替尼用于治疗转移性结直肠癌在整个欧盟、挪威、列支敦士登和冰岛的上市许可时，将会把CHMP的积极意见纳入考虑。如果获得批准，呋喹替尼将成为欧盟批准用于经治转移性结直肠癌的第一个也是唯一一个所有三种血管内皮生长因子受体的选择性抑制剂。目前，欧盟转移性结直肠癌患者可用的治疗选择有限，导致治疗结果不佳。自呋喹替尼在中国上市以来，截至2023年年中已有超过8万名结直肠癌患者接受呋喹替尼治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4398604_ZH98604_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430227913","title":"和黄医药(00013)：武田获得欧洲药品管理局人用药品委员会积极意见支持呋喹替尼用于治疗经治转移性结直肠癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2430227913","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430227913?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:37","pubTimestamp":1714135046,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，其合作伙伴武田取得欧洲药品管理局人用药品委员会建议批准呋喹替尼用于治疗经治的成人转移性结直肠癌患者。欧盟委员会在决定呋喹替尼用于治疗转移性结直肠癌在整个欧盟、挪威、列支敦士登和冰岛的上市许可时，将会把CHMP的积极意见纳入考量。如果获得批准，呋喹替尼将成为欧盟批准用于经治转移性结直肠癌的第一个也是唯一一个所有三种血管内皮生长因子受体的选择性抑制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112266.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430828187","title":"和黄医药(US ADR)上涨2.06%，报18.79美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430828187","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430828187?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:02","pubTimestamp":1714053747,"startTime":"0","endTime":"0","summary":"4月25日，和黄医药(US ADR)(HCM)盘中上涨2.06%，截至22:02，报18.79美元/股，成交24.75万美元。财务数据显示，截至2023年12月31日，和黄医药(US ADR)收入总额8.38亿美元，同比增长96.52%；归母净利润1.01亿美元，同比增长127.93%。大事提醒：5月22日，和黄医药(US ADR)将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/25220240414697.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430627443","title":"和黄医药(00013)上涨5.12%，报30.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430627443","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430627443?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:10","pubTimestamp":1714014609,"startTime":"0","endTime":"0","summary":"4月25日，和黄医药(00013)盘中上涨5.12%，截至11:10，报30.8元/股，成交7740.05万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2023年年报，和黄医药营业总收入59.35亿元、净利润7.14亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/25111040400554.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430430244","title":"和黄医药盘中异动 早盘快速拉升5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430430244","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430430244?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:10","pubTimestamp":1714014601,"startTime":"0","endTime":"0","summary":"2024年04月25日早盘11时10分，和黄医药股票出现异动，股价急速拉升5.12%。截至发稿，该股报30.800港元/股，成交量254.95万股，换手率0.29%，振幅6.31%。和黄医药股票所在的药品行业中，整体涨幅为0.24%。其相关个股中，中国医疗集团、兴科蓉医药、和黄医药涨幅较大，振幅较大的相关个股有联康生物科技集团、泰凌医药、三生制药，振幅分别为12.35%、8.00%、7.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042511100187e83654&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042511100187e83654&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430443743","title":"和黄医药(00013)股价上升5.119%，现价港币$30.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2430443743","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430443743?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:09","pubTimestamp":1714014540,"startTime":"0","endTime":"0","summary":"[上升股]和黄医药(00013) 股价在上午11:09比前收市价上升5.119%，现股价为港币$30.8。至目前为止，今日最高价为$30.8，而最低价为$28.95。总成交量为251.7万股，总成交金额为港币$7.572千万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404252162/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2430164414","title":"南向资金4月24日净买入和黄医药73.04万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2430164414","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430164414?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:31","pubTimestamp":1714008669,"startTime":"0","endTime":"0","summary":"4月24日, 南向资金增持和黄医药73.04万股，连续3日增持。截止当日收盘，港股通共持有和黄医药15261.28万股，占流通股17.51%。港股通增持金额前五个股分别为腾讯控股、中国银行、中国财险、中国石油化工股份、中国移动。和黄医药近5个交易日上涨10.36%，港股通累计增持100.21万股；近20个交易日上涨12.05%，港股通累计减持73.45万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042509435487acf705&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042509435487acf705&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429489839","title":"和黄医药04月24日主力资金流入822万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2429489839","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429489839?lang=zh_cn&edition=full","pubTime":"2024-04-24 16:15","pubTimestamp":1713946514,"startTime":"0","endTime":"0","summary":"04月24日, 和黄医药股价涨3.35%，报收29.30元，成交金额1.11亿元，换手率0.44%，振幅4.41%，量比1.38。和黄医药今日主力资金净流入822万元，连续3日净流入，上一交易日主力净流入326万元，今日环比增加152.15%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为38.46%，平均涨幅为4.75%。该股近5个交易日上涨10.36%，主力资金累计净流入1170万元；近20日主力资金累计净流出773万元，其中净流出天数为12日。该股主力净额占比0.03%，港股市场排名187/2629。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042416152787a9d752&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042416152787a9d752&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429216942","title":"和黄医药：呋喹替尼美国上市两个月销售额达1510万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429216942","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2429216942?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:01","pubTimestamp":1713859305,"startTime":"0","endTime":"0","summary":"快讯正文和黄医药午后股价急升5.39%，触及每股28.35港元截至发稿，和黄医药成交金额高达1.03亿港元。平安证券发布分析报告，指出该公司核心产品销售额实现迅猛增势，其拳头产品呋喹替尼在美国市场表现尤为抢眼。作为美国十年来首个获批治疗转移性结直肠癌的新药，呋喹替尼于2023年11月正式登陆美国市场。令人瞩目的是，上市短短两个月，其在美国市场的销售额迅速攀升至1510万美元，增长势头强劲。下载和讯APP查看快讯，体验更佳>>","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231728538b49fdc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231728538b49fdc9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429154728","title":"和黄医药现涨超5% 机构指公司核心产品销售额保持较快增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2429154728","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2429154728?lang=zh_cn&edition=full","pubTime":"2024-04-23 15:35","pubTimestamp":1713857700,"startTime":"0","endTime":"0","summary":"和黄医药（00013）午后上涨5.39%，现报28.35港元，成交额1.03亿港元。\n　　平安证券指出，公司核心产品销售额保持较快增长，呋喹替尼在美国于2023年11月上市，是美国十多年来首个获批用于治疗转移性结直肠癌的创新靶向疗法，上市仅两个月，美国市场销售额已高达1510万美元，放量迅速。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-23/doc-inasvfmy9544885.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-23/doc-inasvfmy9544885.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429156706","title":"港股异动 | 和黄医药(00013)午后涨近7% 呋喹替尼上市后放量迅速 多款重磅产品大适应症有望获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2429156706","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429156706?lang=zh_cn&edition=full","pubTime":"2024-04-23 14:51","pubTimestamp":1713855096,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药(00013)午后涨近7%，截至发稿，涨6.13%，报28.55港元，成交额9464.06万港元。平安证券指出，公司核心产品销售额保持较快增长，呋喹替尼在美国于2023年11月上市，是美国十多年来首个获批用于治疗转移性结直肠癌的创新靶向疗法，上市仅两个月，美国市场销售额已高达1510万美元，放量迅速。此外，公司多款重磅产品大适应症有望于24年获批或申报NDA，有望不断催化公司价值提升。该行表示，考虑到公司上市产品适应症仍在拓展，同时公司在研管线丰富，管线估值有望进一步提升，维持“推荐”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107417.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429027158","title":"生物医药板块午后发力 药明合联(02268)涨8.59% 机构指行业今年依然有结构性增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2429027158","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2429027158?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:53","pubTimestamp":1713851628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块午后发力走高，药明合联 涨8.59%，荣昌生物涨6.53%，信达生物涨6.48%，康希诺生物涨6.4%，维亚生物涨5.88%，和黄医药涨5.58%，康方生物涨5.41%。华鑫证券表示，2024年1季度行业增长受到同期基数影响较为明显，如零售药店、POCT等，展望2024年全年，1季度高增长方向具有代表性，其增长趋势有望延续，医药行业依然有结构性增量。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935593","is_publish_highlight":false,"gpt_icon":0},{"id":"2429015849","title":"和黄医药(00013)股价上升5.019%，现价港币$28.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2429015849","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429015849?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:38","pubTimestamp":1713850680,"startTime":"0","endTime":"0","summary":"[上升股]和黄医药(00013) 股价在下午01:38比前收市价上升5.019%，现股价为港币$28.25。至目前为止，今日最高价为$28.25，而最低价为$26.9。总成交量为248.112万股，总成交金额为港币$6.853千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404232989/aamm-all-category","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.067},{"period":"1month","weight":0.1308},{"period":"3month","weight":0.5324},{"period":"6month","weight":-0.0304},{"period":"1year","weight":0.2578},{"period":"ytd","weight":0.054}],"compareEarnings":[{"period":"1week","weight":0.0555},{"period":"1month","weight":0.0739},{"period":"3month","weight":0.1471},{"period":"6month","weight":0.0309},{"period":"1year","weight":-0.1071},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司（原名：和黄中国医药科技有限公司）是一家主要从事药品制造及销售的投资控股公司。连同其附属公司，该公司通过两个分部经营业务。肿瘤及免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法，包括涵盖药物发现、开发、生产及监管职能的研发活动，以及支持研发业务的行政活动，还包括通过研发活动开发的药物的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及非处方药物以及消费保健品的销售、推广、生产及分销。","exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}